News AIM Vaccine Co., Ltd.

Equities

6660

CNE100005KF2

Delayed Hong Kong S.E. Other stock markets 10:18:46 2024-05-13 pm EDT			5-day change	1st Jan Change
8.38 ^HKD	+1.21%		-3.16%	+5.48%

Mar. 28	Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3%	MT
Mar. 28	Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3%	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3%	Mar. 28	MT
Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3%	Mar. 28	MT
AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for Haemophilus Influenzae Type B Conjugate Vaccine	Mar. 27	CI
AIM Vaccine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for quadrivalent influenza virus vaccine (MDCK Cells)	Mar. 27	CI
Aim Vaccine Submits Clinical Trial's Pre-Application for Rabies Vaccine	Mar. 27	MT
AIM Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Novel-Process Highly-Effective Human Diploid Rabies Vaccine	Mar. 26	CI
AIM Vaccine Files Pre-Application for Marketing Registration of its Pneumonia Vaccine	Mar. 05	MT
AIM Vaccine Boosts Development of Iterative Pneumonia Series Vaccines	Mar. 04	MT
AIM Vaccine Expediting Development of Iterative Rabies Series Vaccines; Shares Drop 4%	Mar. 04	MT
AIM Vaccine Advances Trial of Meningococcal Vaccine in China; Shares Fall 4%	Mar. 04	MT
AIM Vaccine Expects Wider Loss in 2023; Shares Slide 4%	Mar. 04	MT
AIM Vaccine Submits Pre-Application for Clinical Trials for Absorbed Tetanus Vaccine; Shares Fall 3%	Mar. 04	MT
Aim Vaccine Co., Ltd. Initiation of Phase II Clinical Trial of Tetravalent Meningococcal Conjugate Vaccine	Mar. 03	CI
AIM Vaccine Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023	Mar. 03	CI
Aim Vaccine Co., Ltd. Announces Completion of the Layout of Iterative Rabies Vaccine Products and Fully Advancing the Research and Development of the Product Series	Mar. 03	CI
AIM Vaccine Co., Ltd. Announces Completion of Application for Marketing of 13-Valent Pneumonia Conjugate Vaccine, Iterative Serum-Free Rabies Vaccine and 23-Valent Pneumonia Polysaccharide Vaccine	Mar. 03	CI
Aim Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Absorbed Tetanus Vaccine	Mar. 03	CI
AIM Vaccine Co., Ltd. Submits the Pre- Application for Marketing Registration for Its 13-Valent Pneumonia Conjugate Vaccine	Mar. 01	CI
AIM Vaccine Co., Ltd. Announces Executive Changes	Feb. 29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AIM Vaccine Co., Ltd.

Equities

6660

CNE100005KF2

Summary

Filters